MX2023014944A - Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados. - Google Patents
Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados.Info
- Publication number
- MX2023014944A MX2023014944A MX2023014944A MX2023014944A MX2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A MX 2023014944 A MX2023014944 A MX 2023014944A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- treatment
- deoxynucleosides
- diseases caused
- mitochondrial diseases
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 125000003729 nucleotide group Chemical group 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 208000012268 mitochondrial disease Diseases 0.000 title 1
- 101000969776 Homo sapiens Protein Mpv17 Proteins 0.000 abstract 1
- 208000015376 Mitochondrial DNA depletion syndrome, hepatocerebral form Diseases 0.000 abstract 1
- 102100021273 Protein Mpv17 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000033064 hepatocerebral form mitochondrial DNA depletion syndrome Diseases 0.000 abstract 1
- 201000011543 mitochondrial DNA depletion syndrome 3 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212468P | 2021-06-18 | 2021-06-18 | |
| PCT/US2022/033654 WO2022266237A1 (en) | 2021-06-18 | 2022-06-15 | Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014944A true MX2023014944A (es) | 2024-04-25 |
Family
ID=84526701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014944A MX2023014944A (es) | 2021-06-18 | 2022-06-15 | Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230000890A1 (https=) |
| EP (1) | EP4355336A4 (https=) |
| JP (1) | JP2024522783A (https=) |
| CN (1) | CN117500510A (https=) |
| AU (1) | AU2022291783A1 (https=) |
| CA (1) | CA3222484A1 (https=) |
| IL (1) | IL309421A (https=) |
| MX (1) | MX2023014944A (https=) |
| WO (1) | WO2022266237A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313068A4 (en) * | 2021-03-26 | 2024-12-25 | UCB Biosciences, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10292996B2 (en) * | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| JP6599484B2 (ja) * | 2015-06-17 | 2019-10-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| US10745435B2 (en) * | 2015-11-16 | 2020-08-18 | Cerecor, Inc. | Nucleic acid prodrugs |
| US11628182B2 (en) * | 2018-04-12 | 2023-04-18 | Zogenix Mds, Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
-
2022
- 2022-06-15 US US17/841,193 patent/US20230000890A1/en not_active Abandoned
- 2022-06-15 JP JP2023577845A patent/JP2024522783A/ja active Pending
- 2022-06-15 MX MX2023014944A patent/MX2023014944A/es unknown
- 2022-06-15 CA CA3222484A patent/CA3222484A1/en active Pending
- 2022-06-15 EP EP22825758.0A patent/EP4355336A4/en active Pending
- 2022-06-15 AU AU2022291783A patent/AU2022291783A1/en active Pending
- 2022-06-15 WO PCT/US2022/033654 patent/WO2022266237A1/en not_active Ceased
- 2022-06-15 CN CN202280043337.3A patent/CN117500510A/zh active Pending
- 2022-06-15 IL IL309421A patent/IL309421A/en unknown
-
2024
- 2024-07-12 US US18/771,259 patent/US20250049836A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022291783A1 (en) | 2024-02-01 |
| JP2024522783A (ja) | 2024-06-21 |
| US20230000890A1 (en) | 2023-01-05 |
| EP4355336A1 (en) | 2024-04-24 |
| EP4355336A4 (en) | 2025-05-07 |
| US20250049836A1 (en) | 2025-02-13 |
| CA3222484A1 (en) | 2022-12-22 |
| IL309421A (en) | 2024-02-01 |
| WO2022266237A1 (en) | 2022-12-22 |
| CN117500510A (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388140B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| JOP20190076A1 (ar) | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret | |
| PH12020551332A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2017004128A (es) | Derivados de diarilurea como inhibidores de quinasa p38. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| EA201590391A1 (ru) | Пиразолилмочевины в качестве ингибиторов киназы | |
| EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| EA201790122A1 (ru) | Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| MX2018012275A (es) | Inhibidores de quinasa. | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| MX2023014944A (es) | Profarmacos de desoxinucleosidos para el tratamiento de enfermedades mitocondriales causadas por grupos de nucleosidos desequilibrados. | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| CL2020003070A1 (es) | Selección y uso de bacterias de apoyo de melatonina para reducir el cólico infantil | |
| EA201990940A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| WO2018229551A3 (en) | METHODS OF TREATING A DISORDER RELATED TO THE USE OF OPIOIDS | |
| MX2018013885A (es) | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). | |
| EA201990834A1 (ru) | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний | |
| MX2023006855A (es) | Formas de dosificacion y usos terapeuticos de l-4-cloro quinurenina |